Following the earliest demonstration of the clinical effectiveness of BRAF- and MEK-targeted therapies in patients with advanced unresectable melanoma,14,20 their use has broadened to include their use in the adjuvant setting for treatment, with curative intent, of patients with resected stage III disease.2 This evidence concerns the gene MAP2K7 and melanoma.